Published Paper Details:

Autoimmune joint diseases are characterized by chronic synovial inflammation and immune dysfunction, leading to joint destruction and impaired function. Integrative approaches such as Ayurveda may offer therapeutic potential through multi-targeted strategies addressing symptoms and immune modulation. This study evaluated the clinical effectiveness and immunomodulatory impact of the Researchayu Regimen for Autoimmune Treatment (RRAT) in patients with seropositive autoimmune joint diseases. An open-label, retrospective, single-arm, multicenter study was conducted at five ResearchAYU centers across Maharashtra, India. A total of 55 patients aged 40-85 years with knee pain and positive rheumatoid factor (RA factor) and/or antinuclear antibody (ANA) were included. The RRAT protocol involved structured Ayurvedic oral formulations, topical Shuddhu Lepa, and therapeutic purgation (Sadhyovirechana). Clinical assessments and laboratory investigations (RA factor, ANA, C-reactive protein [CRP], and serum uric acid) were performed at baseline and after 90 days. Statistical analysis included descriptive statistics, McNemar's test for seroconversion, and paired t-tests or Wilcoxon signed-rank tests for continuous variables, with significance at P < 0.05. At day 90, 80.64% of ANA-positive and 81.25% of RA factor-positive participants achieved seroconversion. CRP and serum uric acid levels showed significant reductions of 33.23% and 25.05%, respectively. Clinically, there was a 61.22% mean relief in walking-related pain and a 57.5% resolution of morning stiffness. No serious adverse events were reported. These findings suggest that the RRAT protocol may offer beneficial clinical and immunological effects in autoimmune joint diseases. Prospective randomized controlled trials are needed for further validation.